Sports Medicine Doctors Reviewed 565 Peptide Studies. Their Verdict: The Evidence Is Not There.
DR
Dr. Anna Chereshnevskyi · General Practitioner ·
For years the case for peptides like BPC-157 and TB-500 has been made mostly by the people selling them. At the end of August, a group of sports medicine researchers at UCLA published what they found when they went through the literature themselves.
The review, led by Dr. Thomas Kremen, an associate professor of orthopedic surgery at the David Geffen School of Medicine at UCLA, with medical student Kushagra Tewari, appeared in the American Journal of Sports Medicine. It covered 565 studies on six products: BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu.
Dr. Kremen's summary was blunt: "The evidence that these peptides are effective is just not there."
Why it matters who wrote this
This did not come from a regulator or a consumer safety group. It came from sports medicine and orthopedics, the specialty whose patients are the core market for these products. Torn tendons, sore joints, slow recovery from injury: that is precisely what BPC-157 and TB-500 are sold for.
So when orthopedic surgeons review the literature and report that there is essentially nothing showing meaningful clinical benefit for musculoskeletal conditions, they are speaking directly to the claims made to their own patients.
What they found
- More than two thirds of the 565 studies were in animals only. The animal results on tissue healing varied, and whether they translate to people is uncertain.
- The human research that exists was generally low quality. Studies lacked proper controls and rigorous design.
- For musculoskeletal conditions, there were essentially no studies showing significant clinical benefit. A handful of human studies outside orthopedics showed modest improvements at best.
- One of the largest BPC-157 studies came from a group with a financial interest in the compound.
- A trial of MK-677 was stopped because of the risk of congestive heart failure.
"It's a lot of marketing and very little substance," Dr. Kremen said.
The MK-677 point deserves its own paragraph
MK-677, also called ibutamoren, is technically not a peptide. It is a small molecule that mimics a growth hormone signal, and it is sold on the same websites, often recommended in the same stacks as CJC-1295 and ipamorelin to raise growth hormone.
That makes the halted trial relevant to a lot of people who would never think of themselves as taking a heart failure risk. Stacks are usually assembled from forum advice rather than from any study of the combination, and the one component in this review with a trial stopped for cardiac safety is a common ingredient in them.
The conflict of interest
The finding about BPC-157 funding is worth understanding correctly. A financial interest does not make a study wrong. It does mean the result needs independent replication before anyone leans on it, and in a field with this little human data, one conflicted study can carry a lot of weight in how the compound is marketed.
This is the same pattern we noted with cosmetic peptides, where manufacturer-funded trials looked better than independent ones. It is less a scandal than a reason to ask who paid for the study you are being shown.
What the review does not say
It is fair to be precise here, because the review will be quoted loosely.
It does not show that these compounds do nothing. It shows that nobody has demonstrated, to a reasonable standard in humans, that they do what they are sold for. Animal results are real, and they are a legitimate reason to fund proper trials. They are not a substitute for them.
It also does not claim these products are uniformly dangerous. Its safety concerns are specific: the MK-677 trial, and the broader fact that unregulated products may contain undisclosed or harmful substances. The authors point to past findings of contaminants in unregulated supplements, including heavy metals such as arsenic and lead.
Where this leaves you
None of this will surprise regular readers. It lines up closely with what we found when we looked at the human evidence behind BPC-157 and TB-500: fewer than thirty people in published human studies of BPC-157, and a large animal literature doing most of the work. Independent confirmation from orthopedic researchers is still worth having.
Their practical advice is unglamorous: prioritize the things with actual evidence behind them for recovery, meaning sleep, nutrition, and structured rehabilitation under proper medical supervision. And if you are going to use these products anyway, the risks around what is actually in the vial are real, as we saw with counterfeit retatrutide testing and forged lab certificates.
Sources: UCLA Health: With peptide supplements, marketing outpaces the medicine and Partnership for Safe Medicines, September 8, 2026.
DR
Written by
Dr. Anna Chereshnevskyi
General Practitioner
Dr. Chereshnevskyi is a general practitioner who graduated from Lviv National Medical University and currently practices at a state hospital in Ankara, Turkey. She specialises in primary care and follows the clinical literature on peptide therapies, metabolic health, and longevity research. She contributes to Peptide.pub as a medical reviewer and blog author, translating complex research into plain, evidence-based language.
About Peptide.pub →